- 专利标题： Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
-
申请号： US17428784申请日： 2020-02-05
-
公开(公告)号： US20220000974A1公开(公告)日： 2022-01-06
- 发明人: Yang Liu , Pan Zheng , Xu Wang , Martin Devenport
- 申请人： Oncolmmune, Inc. , Children's Research Institute, Children's National Medical Center
- 申请人地址： US MD Rockville; US DC Washington
- 专利权人： Oncolmmune, Inc.,Children's Research Institute, Children's National Medical Center
- 当前专利权人： Oncolmmune, Inc.,Children's Research Institute, Children's National Medical Center
- 当前专利权人地址： US MD Rockville; US DC Washington
- 国际申请： PCT/US2020/016874 WO 20200205
- 主分类号： A61K38/17
- IPC分类号： A61K38/17 ; C07K14/705 ; A61P3/06 ; A61P3/10
摘要：
Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.
信息查询
IPC分类:
